Flash e-reader

 Go to e-reader chapter








Table 12.6b

Immunosuppression Use for Induction by Discharge Regimen, 2005 to 2009

Recipients with Lung Transplants

  Discharge Regimen (w/ or w/o Steroids Use) All
CyA Tac CyA+ MMF Tac+ MMF CyA+ Aza Tac+ Aza Siro+ MMF Tac+ Siro Other
Functioning Graft with Immunosuppression Info at Discharge 79 413 299 3,593 442 1,710 6 19 241 6,802
% of All Regimens 1.2% 6.1% 4.4% 52.8% 6.5% 25.1% 0.1% 0.3% 3.5% 100.0%
Induction Drug 2.5% 5.3% 3.3% 6.3% 2.3% 7.6% 0.0% 5.3% 9.5% 6.2%
Atgam/NRATG/NRATS
OKT3 1.3% 0.0% 2.7% 0.4% 7.5% 0.4% 0.0% 0.0% 1.7% 1.0%
Thymoglobulin 1.3% 3.1% 3.0% 6.0% 4.3% 1.2% 16.7% 5.3% 9.5% 4.5%
Zenapax 0.0% 3.6% 8.0% 18.7% 5.7% 13.2% 16.7% 5.3% 46.9% 15.8%
Simulect 2.5% 8.7% 21.7% 21.8% 14.0% 39.8% 33.3% 68.4% 66.0% 26.5%
Campath 13.9% 17.9% 6.4% 10.9% 0.0% 0.1% 0.0% 0.0% 29.0% 8.3%
No Induction Drugs Recorded 78.5% 62.0% 55.5% 37.3% 66.7% 38.5% 33.3% 21.1% 47.3% 42.6%


Source: OPTN/SRTR Data as of October 1, 2010.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.

Individual induction drug percentages will not necessarily add up to 100 percent, as patients may be prescribed more than one induction drug.

CyA: Cyclosporine; Tac: Tacrolimus; MMF: Include MMF(Mycophenolate Mofetil) and MPA(Mycophenolate Sodium); Aza: Azathioprine; Siro: Sirolimus.